Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn

Table of Contents

April 01, 2022; Volume 381,Issue 1

Minireview

  • You have access
    Attenuation of Response to Repeated Drug Administration: A Proposal for Differentiating Tachyphylaxis and Tolerance
    Craig K. Svensson
    Journal of Pharmacology and Experimental Therapeutics April 2022, 381 (1) 22-32; DOI: https://doi.org/10.1124/jpet.121.000978

Cellular and Molecular

  • You have access
    Cinnabarinic Acid-Induced Stanniocalcin 2 Confers Cytoprotection against Alcohol-Induced Liver Injury
    Aditya D. Joshi, Gopal Thinakaran and Cornelis Elferink
    Journal of Pharmacology and Experimental Therapeutics April 2022, 381 (1) 1-11; DOI: https://doi.org/10.1124/jpet.121.000999

Chemotherapy, Antibiotics, and Gene Therapy

  • You have access
    Inhibition of Colon Cancer Cell Growth by Phosphodiesterase Inhibitors Is Independent of cGMP Signaling
    Yali Hou, Alexis Wren, Namratha Mylarapu, Kaylin Browning, Bianca N. Islam, Rui Wang, Kenneth J. Vega and Darren D. Browning
    Journal of Pharmacology and Experimental Therapeutics April 2022, 381 (1) 42-53; DOI: https://doi.org/10.1124/jpet.121.001075

Drug Discovery and Translational Medicine

  • Open Access
    A Phase I, First-in-Human, Healthy Volunteer Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CVN424, a Novel G Protein-Coupled Receptor 6 Inverse Agonist for Parkinson’s Disease
    David H. Margolin, Nicola L. Brice, Antonia M. Davidson, Kim L. Matthews and Mark B. L. Carlton
    Journal of Pharmacology and Experimental Therapeutics April 2022, 381 (1) 33-41; DOI: https://doi.org/10.1124/jpet.121.000842

Inflammation, Immunopharmacology, and Asthma

  • Open Access
    Preclinical Immunopharmacologic Assessment of KPL-404, a Novel, Humanized, Non-Depleting Antagonistic Anti-CD40 Monoclonal Antibody
    Sujatha Muralidharan, Moses Njenga, Tracy Garron, Kent Bondensgaard and John F. Paolini
    Journal of Pharmacology and Experimental Therapeutics April 2022, 381 (1) 12-21; DOI: https://doi.org/10.1124/jpet.121.000881

Neuropharmacology

  • You have access
    Opportunities for Precision Treatment of GRIN2A and GRIN2B Gain-of-Function Variants in Triheteromeric N-Methyl-D-Aspartate Receptors
    Wei Han, Hongjie Yuan, James P. Allen, Sukhan Kim, Gil H. Shaulsky, Riley E. Perszyk, Stephen F. Traynelis and Scott J. Myers
    Journal of Pharmacology and Experimental Therapeutics April 2022, 381 (1) 54-66; DOI: https://doi.org/10.1124/jpet.121.001000

Erratum

  • You have access
    Correction to “Central Nervous System Distribution of an Opioid Agonist Combination with Synergistic Activity”
    Journal of Pharmacology and Experimental Therapeutics April 2022, 381 (1) 67; DOI: https://doi.org/10.1124/jpet.121.000821err
Back to top
PreviousNext

In this issue

Journal of Pharmacology and Experimental Therapeutics: 381 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 381, Issue 1
1 Apr 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts

Jump to

  • Minireview
  • Cellular and Molecular
  • Chemotherapy, Antibiotics, and Gene Therapy
  • Drug Discovery and Translational Medicine
  • Inflammation, Immunopharmacology, and Asthma
  • Neuropharmacology
  • Erratum
  • Most Read
Loading
  • Potential Clinical Uses of CBG
  • Ocular Drug Delivery: Past, Present, and Future
  • Rho GTPase–Pathway Inhibitor Reduces Markers of Fibrosis
  • Nose-to-Brain Delivery
  • SEP-363856, a Novel, Non-D2 Psychotropic Agent
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics